Who is Tudekan Tepotinib Hydrochloride Tablets suitable for? How to use it correctly?

With the continuous advancement of medical technology, targeted therapeutic drugs targeting specific gene mutations have brought new hope to cancer patients. Among them, Tudekan Tepotinib Hydrochloride Tablets (trade name: Tudekan) is the world's first oral highly selective MET inhibitor approved for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying mesenchymal epithelial transition factor (MET) exon 14 skipping mutations. It has attracted much attention since it was launched in China in 2023. So, who is this innovative drug suitable for? How to use it correctly?

First of all, we need to clarify the applicable groups of Tudecan Tepotinib Hydrochloride Tablets. This drug is mainly targeted at adult patients with locally advanced or metastatic non-small cell lung cancer who carry MET exon 14 skipping mutations. Although this gene mutation is relatively rare in non-small cell lung cancer, about 2% of NSCLC patients in China have this mutation. For this specific group of patients, Tudekan Tepotinib Hydrochloride Tablets provides a precise treatment plan that helps prolong survival, improve quality of life, and may lead to better treatment effects.

However, it is important to note that not all patients with non-small cell lung cancer are suitable for this drug. Before use, sufficient genetic testing must be performed to confirm that the patient indeed has the MET exon 14 skipping mutation. Only based on such evidence will doctors consider using Tudecan Tepotinib Hydrochloride Tablets for treatment.

Next, let’s take a look at how to use Tudecan Tepotinib Hydrochloride Tablets correctly. The recommended dose of this drug is 450 mg (i.e. 2 tablets) once a day, and it is recommended to take it with food. To ensure the stability and effectiveness of the drug, patients should take it at approximately the same time each day, swallow the tablet whole and avoid chewing, crushing or breaking the tablet. If you occasionally forget to take a dose and the next dose is less than 8 hours away, you do not need to take the missed dose. However, if vomiting occurs after taking a dose, the patient should continue taking the next dose at the originally planned time.

During the treatment process, patients also need to pay special attention to possible adverse reactions. For example, peripheral edema, hypoalbuminemia, nausea, and elevated creatinine are common side effects. If these reactions affect the patient's daily life or the safety of treatment, the doctor may adjust the drug dose on a case-by-case basis. For patients who cannot tolerate higher doses, the dose may need to be reduced to 225 mg (i.e. 1 tablet) once daily, or the product may even need to be permanently discontinued.

In addition, patients need to undergo liver function tests regularly during treatment to monitor possible liver toxicity. In patients with mild or moderate renal impairment, dose adjustment is generally not required. However, patients with severe renal insufficiency should consult a professional physician before use, as the recommended dosage for these patients has not yet been determined.

Finally, special reminder is that Tudekan Tepotinib Hydrochloride Tablets should be used with caution in pregnant and lactating women. The drug may harm the fetus and cause malformations, according to animal studies. Therefore, women of childbearing potential should take effective contraceptive measures during medication and within one week after stopping medication. At the same time, lactating women should also avoid breastfeeding during treatment and within one week after stopping the drug.

To sum up, Tuodekang Tepotinib Hydrochloride Tablets provides a new treatment option for patients with non-small cell lung cancer carryingMET exon 14 skipping mutations. However, its use must be based on strict genetic testing evidence and under the guidance of professional doctors. Patients should strictly abide by the medication method during use, monitor relevant indicators regularly, and communicate with the doctor in a timely manner if adverse reactions occur. At the same time, for special groups such as pregnant women and lactating women, special attention should be paid to medication safety to ensure the effectiveness and safety of treatment.

References:

https://www.drugs.com/pro/tepmetko.html

https://www.drugs.com/tepmetko.html